Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login
Journal of Cancer Research and Therapeutics, a publication of Association of Radiation Oncologists of India (AROI), is a peer-reviewed online journal with Quarterly print on demand compilation of issues published. The journalís full text is available online at http://www.cancerjournal.net. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository.

Editor in Chief
Dr. Nagraj Huilgol

Executive Editor
Rajiv Sarin, Mumbai, India

Associate Editor
Rakesh Jalali, Mumbai, India

View All Members

  • 3,178 Total articles
  • 3,177 Full text articles
  • 855 Manuscripts submitted in '18
  • 125,793 Articles downloaded in 'November 2018

Special Issue

September 2013 Volume 9 | Issue 5 (Supplement)

Special Issue

November 2013 Volume 9 | Issue 7 (Supplement)

December 2018| Vol 14| Issue 12

Review Article

PTEN and SHIP: Impact on lymphatic metastasis in breast cancer

Lymph node metastasis is the most common form of metastasis in breast cancer and a crucial indicator influencing breast cancer treatment results. The biological process of lymph node metastasis invo...

Original Article

Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway

Aim of the Study: Garcinia hanburyi is a traditional herbal medicine with activities of anti-inflammation and hemostasis used by people in South Asia. Gambogic acid (GA) is the main active co...

Original Article

Bleeding risk in cancer patients treated with sorafenib: A meta-analysis of randomized controlled trials

Objective: Sorafenib, an oral vascular endothelial growth factor receptor tyrosine-kinase inhibitor, has become a cornerstone in the treatment of various malignancies. However, concerns have ...

Original Article

Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis

Background: Capecitabine monotherapy is usually used for advanced breast cancer (ABC) resistant to anthracycline and taxane, but there are still many other options too. Our meta-analysis asse...

View All Articles